Open Access

STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas

  • Authors:
    • Nadège Dubois
    • Sharon Berendsen
    • Katherine Tan
    • Laurent Schoysmans
    • Wim Spliet
    • Tatjana Seute
    • Vincent Bours
    • Pierre A. Robe
  • View Affiliations

  • Published online on: September 5, 2022     https://doi.org/10.3892/ijo.2022.5414
  • Article Number: 124
  • Copyright: © Dubois et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The copy number and mRNA expression of STAT5b were assessed in samples from the TCGA repository of glioblastomas (GBM). The activation of this transcription factor was analyzed on tissue microarrays comprising 392 WHO 2016 GBM samples from our clinical practice. These data were correlated with patient survival using multivariable Cox analysis and, for a subset of 167 tumors, with signs of tumor invasiveness on the MRI. The effects of STAT5b knockdown by siRNA were assessed on the growth, therapeutic resistance, invasion and migration of GBM cell lines U87, U87‑EGFRVIII and LN18 and primary cultures GM2 and GM3. The activation, but not the copy number or the mRNA expression of nuclear transcription factor STAT5b expression correlated inversely with patient survival independently of IDH1R132H status, age, Karnofsky Performance Score, treatment and tumor volume. STAT5b inhibition neither altered the cell proliferation nor reduced the clonogenic proliferative potency of GBM cells, and did not sensitize them to the cytotoxic effect of ionizing radiation and temozolomide in vitro. STAT5b inhibition significantly increased GBM cell migration, but decreased the invasion of some GBM cells in vitro. There was no correlation between the activation of STAT5b in clinical tumors and the extent of invasion on MRI OF patients. In conclusion, STAT5b is frequently activated in GBM and correlates inversely with patient survival. It does not contribute to the growth and resistance of these tumors, and is thus rather a potential prognostic marker than a therapeutic target in these tumors.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 61 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dubois N, Berendsen S, Tan K, Schoysmans L, Spliet W, Seute T, Bours V and Robe PA: STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas. Int J Oncol 61: 124, 2022.
APA
Dubois, N., Berendsen, S., Tan, K., Schoysmans, L., Spliet, W., Seute, T. ... Robe, P.A. (2022). STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas. International Journal of Oncology, 61, 124. https://doi.org/10.3892/ijo.2022.5414
MLA
Dubois, N., Berendsen, S., Tan, K., Schoysmans, L., Spliet, W., Seute, T., Bours, V., Robe, P. A."STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas". International Journal of Oncology 61.4 (2022): 124.
Chicago
Dubois, N., Berendsen, S., Tan, K., Schoysmans, L., Spliet, W., Seute, T., Bours, V., Robe, P. A."STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas". International Journal of Oncology 61, no. 4 (2022): 124. https://doi.org/10.3892/ijo.2022.5414